|
井藤 奈央子
Department School of Medicine(Tokyo Women's Medical University Hospital), School of Medicine Position Assistant Professor |
|
| Article types | Original article |
| Language | English |
| Peer review | Peer reviewed |
| Title | Efficacy and safety of eculizumab in childhood atypical hemolytic uremic syndrome in Japan. |
| Journal | Formal name：Clinical and experimental nephrology Abbreviation：Clin Exp Nephrol ISSN code：14377799/13421751 |
| Domestic / Foregin | Foregin |
| Volume, Issue, Page | 20(2),pp.265-72 |
| Author and coauthor | Ito Naoko, Hataya Hiroshi, Saida Ken, Amano Yoshiro, Hidaka Yoshihiko, Motoyoshi Yaeko, Ohta Toshiyuki, Yoshida Yasuhiro, Terano Chikako, Iwasa Tadashi, Kubota Wataru, Takada Hidetoshi, Hara Toshiro, Fujimura Yoshihiro, Ito Shuichi |
| Publication date | 2016/04 |
| Summary | BACKGROUND:Atypical hemolytic uremic syndrome (aHUS) is a severe life-threatening disease with frequent progression to end-stage renal disease (ESRD). Eculizumab, a humanized anti-C5 monoclonal antibody targeting the activated complement pathway, has recently been introduced as a novel therapy against aHUS. We, therefore, investigated the efficacy and safety of eculizumab in Japanese pediatric patients.METHODS:We retrospectively analyzed clinical course and laboratory data of the first ten children with aHUS treated with eculizumab nationwide.RESULTS:Seven patients were resistant to plasma therapy and three were dependent on it. Causative gene mutations were found in five patients. Two patients had anti-complement factor H autoantibody. Three patients had a family history of thrombotic microangiopathy (TMA). After initiation of eculizumab, all patients immediately achieved hematological remission and could successfully discontinue plasma therapy. The median periods to normalization of platelet count, lactate dehydrogenase levels and disappearance of schistocytes were 5.5, 17 and 12 days, respectively. Nine patients recovered their renal function and the median period to terminate renal replacement therapy (RRT) was 3 days. However, two patients progressed to ESRD and required chronic RRT at the last observation. No patients had a relapse of TMA under regular eculizumab therapy. No serious adverse events occurred during the follow-up period.CONCLUSIONS:Eculizumab is efficacious and well-tolerated therapy for children with aHUS. Although pathogenic mutations could not be detected in five patients, all patients showed immediate normalization of hematological abnormalities, strongly suggesting complement-related aHUS. This prompt hematological amelioration can become an indicator for therapeutic efficacy of eculizumab. However, appropriate indications and optimal duration of the treatment remain unclear. |
| DOI | 10.1007/s10157-015-1142-y |
| PMID | 26156042 |